pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$ENSCEnsysce Biosciences, Inc.

$ENSC
La Jolla, CA, USupdated 18d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 2Phase 3: 1
2Phase 11Phase 3
Phase 3
PF-614
Post-Operative Pain
Phase 1
PF614-MPAR
Pain
Phase 1
nafamostat mesylate
Coronavirus Disease 2019 (COVID-19)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase1Single Dose Study, Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (PF614-MPAR-102)recruitingn=30
  • phase3PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301)recruitingn=320
  • phase2Assessment of PF614 Effects on Experimental Pain in the Cold Pressure Test (PF614-201)completedn=16
  • phase1Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)completedn=64
  • phase1Evaluation of Oral PF614 Relative to OxyContin (PF614-102)completedn=84
  • phase1Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)completedn=111
  • phase1A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)completedn=32
  • phase1A Study to Evaluate the Intranasal Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-103)completedn=27
more trials →
🐶 Hiring Signal
No open roles indexed yet — view Ensysce Biosciences, Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$ENSC
SEC CIK
0001716947
country
US
source
sec_tickers
top tags
Infectious Disease1Pain1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 6m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?